The presentation will feature the first clinical results for ART6043 from the Phase 1/2a study ( NCT05898399 ), including safety, tolerability, pharmacokinetics, and preliminary efficacy in patients ...
A common hallmark of viral genome replication is a high mutation rate, which can aid in their ability to evade new treatments and acquire resistance to once-effective antiviral medications. Now, a new ...
STATEN ISLAND, N.Y., Feb. 19, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback